EyePoint Pharmaceuticals, Inc. a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, and ImprimisRx, one of the nation’s leading ophthalmic-focused pharmaceutical businesses and a wholly-owned subsidiary of Harrow Health, Inc. jointly announced the expansion of their commercial alliance in which ImprimisRx will assume responsibility for U.S. sales and marketing activities for DEXYCU® (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery in the U.S. The amended agreement expands the commercial alliance previously established in August 2020 between the companies.
EyePoint Pharmaceuticals is excited to build upon our successful collaboration with ImprimisRx to promote awareness and demand for DEXYCU to cataract surgeons and patients in need of more effective treatments to manage ocular inflammation following surgery,” said Scott Jones, Chief Commercial Officer of EyePoint Pharmaceuticals. “We are dedicated to providing long-lasting solutions to all patients suffering from ophthalmic diseases. This expanded partnership enables us to fully leverage ImprimisRx’s presence and tremendous expertise in ocular and cataract surgery, while allowing EyePoint to focus our efforts on advancing our retinal disease-focused pipeline. We look forward to working closely with the ImprimisRx team to accelerate DEXYCU’s growth, bringing its many benefits to more physicians and patients.”
“We are pleased to expand our partnership with EyePoint to continue to bring DEXYCU, an innovative FDA-approved injectable steroid product, to patients experiencing inflammation following ocular surgery,” said John Saharek, President of ImprimisRx. “A growing number of our ophthalmologist customers experience the benefits DEXYCU offers as a sustained release treatment option that is a complement to their patients’ eye drop regimen. We are pleased with the success we have had thus far in building customer demand for DEXYCU, which we expect to grow as result of the expansion of our partnership with EyePoint. We look forward to executing our U.S. commercial strategy alongside EyePoint to attain our shared goal of even greater success for many years to come.”